生物技术公司库拉肿瘤（Kura Oncology, Inc.，股票代码：KURA）今日盘中大跌5.70%，主要原因是该公司公布的季度财报结果远低于分析师预期。
根据公司最新发布的财报，截至6月30日的季度中，库拉肿瘤调整后每股亏损为0.75美元，远高于分析师平均预期的0.46美元亏损。公司营收仅为1529万美元，同样大幅低于市场预期的3666万美元。这一业绩表现明显弱于预期，引发了投资者的担忧，导致股价大幅下挫。
尽管季度业绩不佳，分析师对库拉肿瘤的长期前景仍持积极态度。目前，分析师对该公司股票的平均评级为"买入"，其中13个评级为"强烈买入"或"买入"，2个为"持有"，没有"卖出"或"强烈卖出"评级。华尔街分析师给出的12个月目标价中位数为28.00美元，较当前股价有显著上涨空间。然而，考虑到公司连续几个季度的业绩表现不及预期，投资者可能需要重新评估其短期增长前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.